We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma firms denied merger.
- Authors
Huggett, Brady
- Abstract
This article reports on the decision of the U.S. Federal Trade Commission (FTC) to deny the proposed acquisition of plasma product company Talecris Biotherapeutics by rival firm CSL in 2009. The FTC authorized a lawsuit challenging the buyout, claiming it was anticompetitive and violated anti-trust laws. The agency added that the deal would reduce the number of competitors in the U.S. markets for immune globulin and albumin.
- Subjects
UNITED States; MERGERS &; acquisitions; CSL Ltd.; TALECRIS Biotherapeutics Inc.; UNITED States. Federal Trade Commission; ACTIONS &; defenses (Law); ECONOMIC competition; ANTITRUST law
- Publication
Nature Biotechnology, 2009, Vol 27, Issue 8, p684
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0809-684b